A guide to treating gait impairment with prolonged-release fampridine (Fampyra (R)) in patients with multiple sclerosis

Autor: Ramio-Torrenta, L, Alvarez-Cermeno, JC, Arroyo, R, Casanova-Estruch, B, Fernandez, O, Garcia-Merino, JA, Hernandez, MA, Izquierdo, G, Martinez-Yelamos, S, Meca, J, Moral, E, Olascoaga, J, Prieto, JM, Saiz, A

Publikováno v: NEUROLOGIA
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname

Introduction: Gait impairment, a frequent sign in multiple sclerosis (MS), places a major burden on patients since it results in progressive loss of personal and social autonomy, along with work productivity. This guide aims to provide recommendation

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::a826b2fe724e2d0b7870b7ffc5397a1b
https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=4872

Pharmacogenomic study in patients with multiple sclerosis: Responders and nonresponders to IFN-β

Autor: Oksenberg, Jorge, Bustamante, MF, Morcillo-Suárez, C, Malhotra, S, Rio, J, Leyva, L, Fernández, O, Zettl, UK, Killestein, J, Brassat, D, García-Merino, JA

Publikováno v: Oksenberg, Jorge; Bustamante, MF; Morcillo-Suárez, C; Malhotra, S; Rio, J; Leyva, L; et al.(2015). Pharmacogenomic study in patients with multiple sclerosis: Responders and nonresponders to IFN-β.. UC San Francisco: Retrieved from: http://www.escholarship.org/uc/item/21d3n5h3

OBJECTIVES: We aimed to investigate the association between polymorphisms located in type I interferon (IFN)-induced genes, genes belonging to the toll-like receptor (TLR) pathway, and genes encoding neurotransmitter receptors and the response to IFN

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_______325::ff7532ed8d48ba2b4fd77195cd002061
http://www.escholarship.org/uc/item/21d3n5h3

Lipid-specific immunoglobulin M bands in cerebrospinal fluid are associated with a reduced risk of developing progressive multifocal leukoencephalopathy during treatment with natalizumab

Autor: Villar LM, Costa-Frossard L, Masterman T, Fernandez O, Montalban X, Casanova B, Izquierdo G, Coret F, Tumani H, Saiz A, Arroyo R, Fink K, Leyva L, Espejo C, Simó-Castelló M, García-Sánchez MI, Lauda F, Llufriú S, Álvarez-Lafuente R, Olascoaga J, Prada A, Oterino A, de Andrés C, Tintoré M, Ramió-Torrentà L, Rodríguez-Martín E, Picón C, Comabella M, Quintana E, Agüera E, Díaz S, Fernandez-Bolaños R, García-Merino JA, Landete L, Menéndez-González M, Navarro L, Pérez D, Sánchez-López F, Serrano-Castro PJ, Tuñón A, Espiño M, Muriel A, Bar-Or A, Álvarez-Cermeño JC

Publikováno v: Digital.CSIC. Repositorio Institucional del CSIC
instname
ANNALS OF NEUROLOGY
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe

[Objective]: Progressive multifocal leukoencephalopathy (PML) is a serious side effect associated with natalizumab treatment in multiple sclerosis (MS). PML risk increases in individuals seropositive for anti–John Cunningham virus (JC) antibodies,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::f85647b8ae30519132457757c9db23a7
http://hdl.handle.net/10261/199269

Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study

Autor: Khatri, B, Barkhof, F, Comi, G, Hartung, Hp, Kappos, L, Montalban, X, Pelletier, J, Stites, T, Wu, S, Holdbrook, F, Zhang auberson, L, Francis, G, Cohen, Ja, Cohen, J, Easton, Jd, Calandra, T, Dimarco, J, Hudson, L, Kesselring, J, Laupacis, A, Temkin, N, Weinshenker, B, Zarbin, M, Poppe, P, Luetic, G, Cristiano, E, Caceres, F, Garcea, O, Correale, J, Ballario, C, Piedrabuena, R, Pollard, J, Beran, R, Hodgkinson, S, Schwartz, R, Heard, R, King, J, Butzkueven, H, Maida, Em, Vass, K, Franta elmer, C, Berger, T, Aichner, F, Ladurner, G, Bissay, V, Sindic, C, D'Hooghe, M, Mulleners, E, Damasceno, B, Barreira, A, Naylor, R, Alvarenga, R, Bacellar, A, Haussen, S, Duquette, P, Antel, J, Lamontagne, A, Grand'Maison, F, Freedman, M, Christie, S, O'Connor, P, Vorobeychik, G, Devonshire, V, Ramadan, M, Hamdy, S, Reda, E, Hashem, S, Fouad, M, Lebrun frenay, C, Clanet, M, Brochet, B, Debouverie, M, Heinzlef, O, Ziemssen, T, Koehler, W, Tiel wilck, K, Bachus, R, Altmann, N, Faiss, J, Baum, K, Dressel, A, Luckner, K, Ebke, M, Stangel, M, Diener, Hc, Bethke, F, Limmroth, V, Maschke, M, Thoemke, F, Reifschneider, G, Diehm, R, Wildemann, B, Melms, A, Rauer, S, Karlbauer, G, Berthele, A, Lang, M, Tumani, H, Krauseneck, P, Klein, M, Papadimitriou, A, Karageorgiou, K, Liakopoulos, D, Tascos, N, Plaitakis, A, Papathanasopoulos, P, Panczel, G, Jakab, G, Csiba, L, Komoly, S, Csanyi, A, Bartos, L, Centonze, D, Pozzilli, C, Marrosu, Mg, Bertolotto, A, Mancardi, GIOVANNI LUIGI, Scarpini, E, Protti, A, Ghezzi, A, Capra, R, Bergamaschi, R, Gallo, P, Stecchi, S, Montanari, E, Tola, Mr, Amato, Mp, Silvestrini, M, Lugaresi, A, Trojano, M, Morra, Vb, Ruggieri, S, Patti, F, Kim, Sm, Lee, Kh, Kim, Hj, Park, Sp, Ginestal, R, Salgado, Av, Fontoura, P, Cunha, L, Sousa, L, Mj, Sá, Pedrosa, R, Arbizu, T, Arroyo, R, Merino, Ja, Fernandez, O, Izquierdo, G, Casanova, B, Antigüedad, A, Goebels, N, Young, C, Lee, M, Chaudhuri, A, Nicholas, R, Martinez, Ac, Preiningerova, J, Greco, D, Gross, J, Newman, S, Mitchell, G, Pawar, G, Freedman, Sm, Kaufman, M, Absher, J, Kantor, D, Ayala, R, Honeycutt, W, Shafer, S, Steingo, B, Delgado, S, Cascione, M, Brock, C, Keegan, A, Laganke, C, Hunter, S, Wilson, E, Mazhari, A, Bauer, W, Singer, B, Lynch, S, Rowe, V, Hutton, G, Gazda, S, Dihenia, B, Campagnolo, D, Chippendale, T, Ash, P, Jung, L, Olek, M.

Publikováno v: Lancet Neurology, 10(6), 520-529. Lancet Publishing Group
Khatri, B, Barkhof, F, Comi, G, Hartung, H P, Kappos, L, Montalban, X, Pelletier, J, Stites, T, Wu, S, Holdbrook, F, Zhang-Auberson, L, Francis, G & Cohen, J A 2011, ' Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study ', Lancet Neurology, vol. 10, no. 6, pp. 520-529 . https://doi.org/10.1016/S1474-4422(11)70099-0
The Lancet Neurology, Vol. 10, no. 6, p. 520-529 (2011)

In a 12-month phase 3 study in patients with relapsing-remitting multiple sclerosis (RRMS), TRANSFORMS, fingolimod showed greater efficacy on relapse rates and MRI outcomes compared with interferon beta-1a. We had two aims in our extension: to compar

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e1b6b2b6d615d53be257bbae8c177cf2
https://research.vumc.nl/en/publications/3df38b4b-0d43-4821-a26d-c5a1be088332

High-pT results and parton density functions from ATLAS

Autor: Merino Javier Llorente

Publikováno v: EPJ Web of Conferences, Vol 270, p 00002 (2022)

The ATLAS detector at the LHC is an ideal experiment to rigorously test QCD in a large variety of final states. This talk will focus on recent results over a wide range of energies, which are particularly sensitive to parton density functions. We wil

Externí odkaz: https://doaj.org/article/3528769588ba463a8ce4044cf24f0fce